Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:EDITNASDAQ:NTLANASDAQ:VIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.33-2.9%$1.46$1.10▼$2.43$73.93M2.92143,833 shs63,678 shsEDITEditas Medicine$1.97-9.6%$1.56$0.91▼$6.05$164.92M2.12.57 million shs3.05 million shsNTLAIntellia Therapeutics$8.31-0.5%$8.09$5.90▼$28.18$860.78M2.142.81 million shs3.28 million shsVIVOMeridian Bioscience$33.97$33.70$20.35▼$34.38$1.50B0.23973,737 shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%-5.67%-15.82%+8.57%-40.89%EDITEditas Medicine0.00%+3.14%+30.46%+39.72%-61.07%NTLAIntellia Therapeutics0.00%+2.72%-2.24%-13.26%-66.96%VIVOMeridian Bioscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.5502 of 5 stars3.55.00.00.03.12.50.6EDITEditas Medicine4.2278 of 5 stars3.12.00.04.22.82.51.3NTLAIntellia Therapeutics4.5968 of 5 stars4.31.00.04.72.72.51.3VIVOMeridian BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.00200.75% UpsideEDITEditas Medicine 2.29Hold$5.36172.27% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$34.95320.58% UpsideVIVOMeridian Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTLA, VIVO, EDIT, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$47.63M1.55N/AN/A$1.52 per share0.88EDITEditas Medicine$35.84M4.60N/AN/A$4.27 per share0.46NTLAIntellia Therapeutics$45.57M18.89N/AN/A$11.73 per share0.71VIVOMeridian Bioscience$333.02M4.49$1.78 per share19.13$8.41 per share4.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)EDITEditas Medicine-$153.22M-$3.04N/AN/AN/A-340.96%-80.13%-50.99%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%8/14/2025 (Estimated)VIVOMeridian Bioscience$42.46M$0.9735.02∞N/A12.70%16.74%13.09%N/ALatest NTLA, VIVO, EDIT, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AVIVOMeridian BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.481.781.78EDITEditas MedicineN/A3.753.75NTLAIntellia TherapeuticsN/A6.736.73VIVOMeridian Bioscience0.073.632.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%EDITEditas Medicine71.90%NTLAIntellia Therapeutics88.77%VIVOMeridian Bioscience89.72%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%EDITEditas Medicine2.10%NTLAIntellia Therapeutics3.10%VIVOMeridian Bioscience2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableVIVOMeridian Bioscience70244.01 million43.00 millionOptionableNTLA, VIVO, EDIT, and CLLS HeadlinesRecent News About These CompaniesMeridian Bioscience Introduces New Enzyme Stabilization Services for Molecular DiagnosticsApril 24, 2025 | finance.yahoo.comMeridian Bioscience Inc (VIVO)April 10, 2025 | uk.investing.comIndia's smartphone mkt grows 6%, Vivo topsNovember 13, 2024 | rediff.comMeridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to SustainabilityNovember 7, 2024 | finance.yahoo.comMeridian Bioscience Gets $500K Top Prize in POC Blood Lead Test ChallengeOctober 28, 2024 | 360dx.comPrecision BioSciences Launches First Hepatitis B Gene-Editing TrialOctober 26, 2024 | precisionmedicineonline.comWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comEditas strengthens in vivo gene therapy strategy via $238M LNP tech pact with GenevantOctober 22, 2024 | fiercebiotech.comVivo and Arm collaborate on chip technology innovation, launch joint labOctober 21, 2024 | digitimes.comvivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint LabOctober 18, 2024 | malaysiasun.comMeridian Growth Legacy MERDXOctober 17, 2024 | morningstar.comSerán Bioscience snags investment from Bain Capital Life SciencesSeptember 17, 2024 | pehub.comVivo T3 Ultra launch on September 12 – check what’s in store for India marketSeptember 6, 2024 | financialexpress.comVivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comFast-growing MBX Biosciences raises another $63.5 million in fundingAugust 6, 2024 | ibj.comMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comGrant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systemsMay 17, 2024 | bioworld.comBiomerica, Inc. (BMRA)May 11, 2024 | finance.yahoo.comVivo X100s Pro with new Dimensity 9300 Plus chip could be launching soonMarch 24, 2024 | gizmochina.comVivo V30 Pro review: Flagship-grade imaging system in a slender form factorMarch 13, 2024 | business-standard.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverNTLA, VIVO, EDIT, and CLLS Company DescriptionsCellectis NASDAQ:CLLS$1.33 -0.04 (-2.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.39 +0.06 (+4.21%) As of 06:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Editas Medicine NASDAQ:EDIT$1.97 -0.21 (-9.63%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.47%) As of 06:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$8.31 -0.04 (-0.48%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.58 +0.27 (+3.25%) As of 06:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Meridian Bioscience NASDAQ:VIVOMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
